NFKB1 and idiopathic pulmonary fibrosis: To sum up, experiments of this study revealed that HSYA may be used for a therapeutic agent for IPF treatment based on the finding that HSYA suppresses TNF-α induced proliferation and inflammatory response of FB through inhibiting the NF-κB/AP-1 signaling pathway.